Abstract: Disclosed are pharmaceutical compositions containing, as the active ingredients, a mixture of a hyaluronic acid polymer with a bradykinin B2 receptor antagonist. Said compositions have proved especially effective in the treatment of degenerative joint diseases such as osteoarthritis using intra-articular injections.

Abstract: Disclosed are pharmaceutical compositions containing, as the active ingredients, a mixture of a hyaluronic acid polymer with a bradykinin B2 receptor antagonist. Said compositions have proved especially effective in the treatment of degenerative joint diseases such as osteoarthritis using intra-articular injections.

Abstract: Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a —NR1R2 amino group in which R1 and R2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a —NR3R4R5 quaternary ammonium group in which R3, R4, R5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.

Abstract: Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt. These BK receptor antagonists are a novel class of medicaments which can be used in all the disorders in which the receptors are involved.

Abstract: Disclosed are non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group. Also disclosed are pharmaceutical compositions containing the compound, and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptor.

Abstract: Non-peptide compounds of formula (I) having activity as specific antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an alpha, alpha-disubstituted amino acid at least one amino group, free or salified, or the corresponding ammonium quaternary salt.

Abstract: This invention relates to novel compounds of general formula (I): ##STR1## and to pharmaceutical compositions containing them.

Abstract: Tachyikinin antagonist compounds of the general formula: ##STR1## are described where: X1, X2, X3, X4, X5, and X6 are identical or different and are --NR'--CO-- or --CO--NR"--, where R' is H or C.sub.1-3 alkyl;Y is --CONR--, --NRCO--, OCO, --COO--, --CH.sub.2 --NR--, --NR--CH.sub.2 --, --SS--, --CH.sub.2 --CH.sub.2 --, cis or trans --CH.dbd.CH-- where R is H or C.sub.1-3 alkyl;R1, R2, R3, and R4 are each a hydrophobic group;n and m are identical or different and are each a whole number from 1 to 4. The preparation and pharmaceutical compositions of the compounds are also disclosed.